Osiris Therapeutics, Inc. Receives Approval From Health Canada To Conduct Phase III Clinical Trial For Lead Stem Cell Drug

BALTIMORE--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR) has received regulatory approval to expand patient enrollment into Canada for its ongoing Phase III pivotal trial evaluating PROCHYMAL™ for the treatment of Graft vs. Host Disease.